www.theepochtimes.com/n2/content/view/24505/

 

Eli Lilly and Co., a global pharmaceutical firm, intends to reduce its staff by 35,000 people over the next two years. The Wall Street Journal Health blog recently reported that Eli Lilly actually hired more workers in 2009 by 350 people. The disconcerting news is that this company is hiring in China and other markets, while reducing its workforce in the United States.

 

 

 

 

drugstorenews.com/%28S%28ahzq14nxuqdn25aa4qthbzvy%29%29/story.aspx?id=121597&menuid=335

 

COPENHAGEN (Nov. 6) Genmab will shut down a manufacturing plant in the United States and lay off employees, the company announced.

The Danish biotech company said it would sell its plant in Brooklyn Park, Minn., and reduce its workforce by 300 as part of a reorganization plan in hopes of saving $60 million.

The company instead will focus on innovation and developing monoclonal antibodies for treating cancer, such as the investigational head and neck cancer drug zalutumumab. Genmab and partner GlaxoSmithKline won approval from the Food and Drug Administration last month for the leukemia drug Arzerra (ofatumumab).

 

The patents on many big name drugs are set to expire and there are no products to replace them.  They are also being killed by other countries openly making generic versions of their top earning drugs but they are powerless to stop the companies.

 

The H1B door has also been slammed shut.

I doubt that they are killed by small drug companies of other countries that make only generic drugs. Those small drug companies survive almost exclusively on government-sponsored health care program. They can't win any contract in those single-payer systems anyway, unless they have monopoly on patented drugs. After all, the medical technology is just about to enter a great leap forward. New research such as this:

 

link